An update on maternal medication‐related embryopathies
| Autor: | Debra Kennedy, Willem Gheysen |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Drug-Related Side Effects and Adverse Reactions Context (language use) 030105 genetics & heredity 03 medical and health sciences Fetus 0302 clinical medicine Pregnancy Humans Medicine Intensive care medicine Prescribed medications Genetics (clinical) 030219 obstetrics & reproductive medicine business.industry Potential risk Obstetrics and Gynecology Prenatal Care medicine.disease Pregnancy Complications Fetal Diseases Teratogens Prenatal Exposure Delayed Effects embryonic structures Planned pregnancy Female business Cohort study |
| Zdroj: | Prenatal Diagnosis. 40:1168-1177 |
| ISSN: | 1097-0223 0197-3851 |
| DOI: | 10.1002/pd.5764 |
| Popis: | There is a general perception that any exposure to medication during pregnancy poses a potential risk to the fetus. Most available data about teratogenic drugs is derived from animal studies, case reports, or cohort studies. As a result, counseling women and their partners about the safety of drugs during pregnancy can be difficult due to limited information about efficacy, pharmacokinetics, and teratogenicity of some drugs. However, this should always be done in the context of weighing up potential teratogenic risks with the perinatal risks of an untreated medical or psychiatric condition. Ideally, this counseling should occur prior to a planned pregnancy so that medications and treatment of chronic medical conditions can be optimized. It is important that clinicians providing antenatal care are able to confidently manage women including utilizing appropriate resources. This paper aims at reviewing a selected (non-exhaustive) list of the most commonly prescribed medications considered significant human teratogens and provides recommendations for pre-conception and antenatal counseling. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text